JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity
NCT06852391
Not Yet Recruiting
The Joule MARS study is a single center, randomized, open label clinical trial aiming to explore the metabolic adaptations that occur in response to weight management in adolescents with obesity. Behavioural lifestyle intervention with and without a pharmacological intervention - semaglutide- will be studied. Study participants will be randomized to one of two groups. Group A will follow a behavioral lifestyle program (BLP) alone for 6 months, followed by BLP and treatment with semaglutide for s... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
03/20/2025
Locations: McMaster University, Hamilton, Ontario
Conditions: Obesity (Disorder)
Register for Updates
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
NCT03819153
Completed
The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will get semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is decided by chance. Semaglutide is a medicine, doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Dr. Terence Hart, Tuscumbia, Alabama +412 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes
NCT04707469
Completed
This study compares three doses of once daily semaglutide tablets in people with type 2 diabetes who were previously treated with other oral anti-diabetic medicines. Participants will be initiated on the lowest starting dose of 3 mg and gradually increased until they reach the final trial dose of 14 mg, 25 mg or 50 mg once daily semaglutide tablets. The final three doses will be randomized (i.e., decided by chance). Participants will be administered one tablet per day for 68 weeks. Women cannot... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: American Clinical Trials, Buena Park, California +180 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
NCT06388187
Active Not Recruiting
This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance. The study will last for about 1½ years for each participant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Aurora FDRC Inc., Costa Mesa, California +23 locations
Conditions: Obesity
Register for Updates
Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity
NCT04788511
Completed
This study will look at how the participants daily life is affected by their heart failure. The study will also look at the change in participants body weight from the start to the end of the study. This is to compare the effect on heart failure symptoms and on body weight in people taking semaglutide (a new medicine) to people taking "dummy" medicine. Participants will either get semaglutide or "dummy" medicine - which treatment participants get is decided by chance. Participants will need to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: Eastern Shore Rsrch Inst, LLC, Fairhope, Alabama +92 locations
Conditions: Obesity
Register for Updates
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
NCT05938712
Recruiting
The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Toronto General Hospital, Toronto, Ontario
Conditions: Kidney Transplant Recipients
Register for Updates
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
NCT04971785
Completed
The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), and understand whether they cause fibrosis improvement and Nonalcoholic Steatohepatitis (NASH) resolution in participants with cirrhosis due to NASH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/07/2025
Locations: University of Alabama at Birmingham Hospital, Birmingham, Alabama +241 locations
Conditions: Nonalcoholic Steatohepatitis
Register for Updates
Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
NCT06764056
Not Yet Recruiting
The goal of this clinical trial is to improve the treatment of hepatic steatosis associated with obesity with pharmacological and nutritionnal approaches. The main question it aims to answer is: Does an individualized nutritionnal approach with a dietician combined with medication targeting obesity is the most efficient way to treat hepatic steatosis associated with obesity? Participants will either participate in one of three groups: * Nutrition: Participant will only have a regular follow-u... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec, Quebec
Conditions: Metabolic Associated Fatty Liver Disease, Metabolic Associated-dysfunction Steatohepatitis (MASH), Obesity
Register for Updates
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
NCT05891496
Active Not Recruiting
The study is being conducted to understand how the medicine, semaglutide, affects the immune system and other biological processes in people with Alzheimer's disease. Semaglutide is a medicine that doctors can prescribe in some countries for the treatment of type 2 diabetes and excess body weight. This study will help us understand whether semaglutide can also be used for the treatment of Alzheimer's disease. The study will last for about 77 weeks. In the first 12 weeks of treatment, participant... Read More
Gender:
ALL
Ages:
Between 55 years and 75 years
Trial Updated:
01/02/2025
Locations: Banner Sun Health Research Institute, Sun City, Arizona +9 locations
Conditions: Alzheimers Disease
Register for Updates
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
NCT05649137
Completed
This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking "dummy" medicine and a lower dose of semaglutide. In addition to taking the medicine, participants will have talks with study staff about healthy food choices and how to be more physically active. Participants will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +66 locations
Conditions: Obesity, Diabetes Mellitus, Type 2
Register for Updates
Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide
NCT06387199
Recruiting
A closed-loop insulin system, often labelled the "artificial pancreas" (AP), consists of an insulin pump, a continuous glucose monitor, and an interface coordinating between them to regulate insulin dosage based on glucose levels. Primarily designed for managing type 1 diabetes, this system has demonstrated significant benefits in previous studies. Yet, despite these advantages, certain challenges persist. Semaglutide, utilized in treating type 2 diabetes and obesity, is a once-weekly injectabl... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/13/2024
Locations: Research Institute of the McGill University Health Centre, Montreal, Quebec
Conditions: Type 1 Diabetes, Diabetes Mellitus
Register for Updates
A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus
NCT04515849
Completed
A Phase 2b, study to measure the effect of Cotadutide at different doses versus placebo or comparator (semaglutide) in participants who have Chronic Kidney Disease with Type 2 Diabetes Mellitus.
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
12/06/2024
Locations: Research Site, Box Hill, Not set +82 locations
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Register for Updates